menthol-glucuronide and Abdominal-Pain

menthol-glucuronide has been researched along with Abdominal-Pain* in 1 studies

Trials

1 trial(s) available for menthol-glucuronide and Abdominal-Pain

Article	Year
A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers. Advances in therapy, 2018, Volume: 35, Issue:11 Peppermint oil (PO) has been shown to reduce abdominal pain in patients with irritable bowel syndrome (IBS). PO is assumed to induce intestinal smooth muscle relaxation and desensitization of nociceptive nerve afferents. To increase colonic PO concentration, an ileocolonic release peppermint oil (IC-PO) capsule has been developed. The aim of this study was to compare pharmacokinetic parameters of the currently available small intestinal release PO (SI-PO) and the novel IC-PO.. In this randomized, double-blind, crossover study, subjects received 182 mg of either SI-PO or IC-PO in a crossover design with a washout period of more than 14 days. Blood samples were collected to determine menthol glucuronide concentrations.. IC-PO has a significantly delayed peak menthol glucuronide concentration and T. ClinicalTrials.gov identifier, NCT02291445, EudraCT database 2014-004195-32. Topics: Abdominal Pain; Adult; Biological Availability; Capsules; Cross-Over Studies; Double-Blind Method; Female; Glucuronates; Healthy Volunteers; Humans; Irritable Bowel Syndrome; Male; Mentha piperita; Menthol; Muscle, Smooth; Parasympatholytics; Plant Oils	2018

Article

Year

A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers.

Advances in therapy, 2018, Volume: 35, Issue:11

Peppermint oil (PO) has been shown to reduce abdominal pain in patients with irritable bowel syndrome (IBS). PO is assumed to induce intestinal smooth muscle relaxation and desensitization of nociceptive nerve afferents. To increase colonic PO concentration, an ileocolonic release peppermint oil (IC-PO) capsule has been developed. The aim of this study was to compare pharmacokinetic parameters of the currently available small intestinal release PO (SI-PO) and the novel IC-PO.. In this randomized, double-blind, crossover study, subjects received 182 mg of either SI-PO or IC-PO in a crossover design with a washout period of more than 14 days. Blood samples were collected to determine menthol glucuronide concentrations.. IC-PO has a significantly delayed peak menthol glucuronide concentration and T. ClinicalTrials.gov identifier, NCT02291445, EudraCT database 2014-004195-32.

Topics: Abdominal Pain; Adult; Biological Availability; Capsules; Cross-Over Studies; Double-Blind Method; Female; Glucuronates; Healthy Volunteers; Humans; Irritable Bowel Syndrome; Male; Mentha piperita; Menthol; Muscle, Smooth; Parasympatholytics; Plant Oils

2018